vs

Side-by-side financial comparison of KENNAMETAL INC (KMT) and West Pharmaceutical Services (WST). Click either name above to swap in a different company.

West Pharmaceutical Services is the larger business by last-quarter revenue ($805.0M vs $592.6M, roughly 1.4× KENNAMETAL INC). West Pharmaceutical Services runs the higher net margin — 16.4% vs 10.3%, a 6.1% gap on every dollar of revenue. On growth, KENNAMETAL INC posted the faster year-over-year revenue change (21.8% vs 7.5%). Over the past eight quarters, West Pharmaceutical Services's revenue compounded faster (7.6% CAGR vs 4.4%).

Kennametal, Inc. is a manufacturer of high-performance cutting tools and engineered components used in the aerospace, defense, transportation and oil and gas drilling industries. Its customer base is global.

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. Founded in 1923 by Herman O. West and J.R. Wike of Philadelphia, the company is headquartered in Exton, Pennsylvania. In its early years of development, West produced rubber components for packaging injectable drugs, providing a sterile environment for the producers of penicillin and insulin.

KMT vs WST — Head-to-Head

Bigger by revenue
WST
WST
1.4× larger
WST
$805.0M
$592.6M
KMT
Growing faster (revenue YoY)
KMT
KMT
+14.3% gap
KMT
21.8%
7.5%
WST
Higher net margin
WST
WST
6.1% more per $
WST
16.4%
10.3%
KMT
Faster 2-yr revenue CAGR
WST
WST
Annualised
WST
7.6%
4.4%
KMT

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
KMT
KMT
WST
WST
Revenue
$592.6M
$805.0M
Net Profit
$61.1M
$132.1M
Gross Margin
35.1%
37.8%
Operating Margin
13.4%
19.5%
Net Margin
10.3%
16.4%
Revenue YoY
21.8%
7.5%
Net Profit YoY
85.0%
1.5%
EPS (diluted)
$0.75
$1.82

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
KMT
KMT
WST
WST
Q1 26
$592.6M
Q4 25
$529.5M
$805.0M
Q3 25
$498.0M
$804.6M
Q2 25
$516.4M
$766.5M
Q1 25
$486.4M
$698.0M
Q4 24
$482.1M
$748.8M
Q3 24
$481.9M
$746.9M
Q2 24
$543.3M
$702.1M
Net Profit
KMT
KMT
WST
WST
Q1 26
$61.1M
Q4 25
$33.9M
$132.1M
Q3 25
$23.3M
$140.0M
Q2 25
$21.6M
$131.8M
Q1 25
$31.5M
$89.8M
Q4 24
$17.9M
$130.1M
Q3 24
$22.1M
$136.0M
Q2 24
$37.2M
$111.3M
Gross Margin
KMT
KMT
WST
WST
Q1 26
35.1%
Q4 25
32.8%
37.8%
Q3 25
31.0%
36.6%
Q2 25
28.2%
35.7%
Q1 25
32.1%
33.2%
Q4 24
30.1%
36.5%
Q3 24
31.3%
35.4%
Q2 24
31.5%
32.8%
Operating Margin
KMT
KMT
WST
WST
Q1 26
13.4%
Q4 25
9.9%
19.5%
Q3 25
7.5%
20.8%
Q2 25
6.1%
20.1%
Q1 25
9.1%
15.3%
Q4 24
6.6%
21.3%
Q3 24
7.5%
21.6%
Q2 24
11.3%
18.0%
Net Margin
KMT
KMT
WST
WST
Q1 26
10.3%
Q4 25
6.4%
16.4%
Q3 25
4.7%
17.4%
Q2 25
4.2%
17.2%
Q1 25
6.5%
12.9%
Q4 24
3.7%
17.4%
Q3 24
4.6%
18.2%
Q2 24
6.8%
15.9%
EPS (diluted)
KMT
KMT
WST
WST
Q1 26
$0.75
Q4 25
$0.44
$1.82
Q3 25
$0.30
$1.92
Q2 25
$0.28
$1.82
Q1 25
$0.41
$1.23
Q4 24
$0.23
$1.78
Q3 24
$0.28
$1.85
Q2 24
$0.47
$1.51

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
KMT
KMT
WST
WST
Cash + ST InvestmentsLiquidity on hand
$106.8M
$791.3M
Total DebtLower is stronger
$597.4M
$202.8M
Stockholders' EquityBook value
$3.2B
Total Assets
$2.7B
$4.3B
Debt / EquityLower = less leverage
0.06×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
KMT
KMT
WST
WST
Q1 26
$106.8M
Q4 25
$129.3M
$791.3M
Q3 25
$103.5M
$628.5M
Q2 25
$140.5M
$509.7M
Q1 25
$97.5M
$404.2M
Q4 24
$121.2M
$484.6M
Q3 24
$119.6M
$490.9M
Q2 24
$128.0M
$446.2M
Total Debt
KMT
KMT
WST
WST
Q1 26
$597.4M
Q4 25
$597.2M
$202.8M
Q3 25
$597.0M
$202.7M
Q2 25
$596.8M
$202.6M
Q1 25
$596.6M
$202.6M
Q4 24
$596.4M
$202.6M
Q3 24
$596.2M
$202.6M
Q2 24
$596.0M
$205.8M
Stockholders' Equity
KMT
KMT
WST
WST
Q1 26
Q4 25
$1.3B
$3.2B
Q3 25
$1.3B
$3.1B
Q2 25
$1.3B
$2.9B
Q1 25
$1.2B
$2.7B
Q4 24
$1.2B
$2.7B
Q3 24
$1.3B
$2.8B
Q2 24
$1.2B
$2.6B
Total Assets
KMT
KMT
WST
WST
Q1 26
$2.7B
Q4 25
$2.6B
$4.3B
Q3 25
$2.5B
$4.1B
Q2 25
$2.5B
$4.0B
Q1 25
$2.5B
$3.6B
Q4 24
$2.4B
$3.6B
Q3 24
$2.5B
$3.7B
Q2 24
$2.5B
$3.5B
Debt / Equity
KMT
KMT
WST
WST
Q1 26
Q4 25
0.45×
0.06×
Q3 25
0.46×
0.07×
Q2 25
0.46×
0.07×
Q1 25
0.48×
0.08×
Q4 24
0.49×
0.08×
Q3 24
0.47×
0.07×
Q2 24
0.48×
0.08×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
KMT
KMT
WST
WST
Operating Cash FlowLast quarter
$251.1M
Free Cash FlowOCF − Capex
$175.0M
FCF MarginFCF / Revenue
21.7%
Capex IntensityCapex / Revenue
9.5%
Cash ConversionOCF / Net Profit
1.90×
TTM Free Cash FlowTrailing 4 quarters
$468.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
KMT
KMT
WST
WST
Q1 26
Q4 25
$55.1M
$251.1M
Q3 25
$17.5M
$197.2M
Q2 25
$78.6M
$177.1M
Q1 25
$28.8M
$129.4M
Q4 24
$55.2M
$190.1M
Q3 24
$45.7M
$180.1M
Q2 24
$113.6M
$165.0M
Free Cash Flow
KMT
KMT
WST
WST
Q1 26
Q4 25
$42.4M
$175.0M
Q3 25
$-5.5M
$133.9M
Q2 25
$57.1M
$101.9M
Q1 25
$5.3M
$58.1M
Q4 24
$35.9M
$85.2M
Q3 24
$21.0M
$98.8M
Q2 24
$90.3M
$64.8M
FCF Margin
KMT
KMT
WST
WST
Q1 26
Q4 25
8.0%
21.7%
Q3 25
-1.1%
16.6%
Q2 25
11.1%
13.3%
Q1 25
1.1%
8.3%
Q4 24
7.5%
11.4%
Q3 24
4.4%
13.2%
Q2 24
16.6%
9.2%
Capex Intensity
KMT
KMT
WST
WST
Q1 26
Q4 25
2.4%
9.5%
Q3 25
4.6%
7.9%
Q2 25
4.2%
9.8%
Q1 25
4.8%
10.2%
Q4 24
4.0%
14.0%
Q3 24
5.1%
10.9%
Q2 24
4.3%
14.3%
Cash Conversion
KMT
KMT
WST
WST
Q1 26
Q4 25
1.63×
1.90×
Q3 25
0.75×
1.41×
Q2 25
3.64×
1.34×
Q1 25
0.92×
1.44×
Q4 24
3.08×
1.46×
Q3 24
2.07×
1.32×
Q2 24
3.06×
1.48×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

KMT
KMT

Americas$298.3M50%
EMEA$174.0M29%
Asia Pacific$120.3M20%

WST
WST

Proprietary Products$661.8M82%
Contract Manufactured Products$143.2M18%
Affiliated Entity$3.3M0%

Related Comparisons